Latest filing published 26 Aug 2026 for Ocular Therapeutix, INC, €200k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Pravin Dugel discloses dealings in 3 companies, chiefly Ocular Therapeutix, Inc, IVERIC bio, Inc. and Whitehawk Therapeutics, Inc. The record holds 34 filings, for trades running from 30 June 2021 to 25 August 2026.
No open-market purchase appears, only 11 sales worth €2.6M. Outside the open market, there are 3 share grants and 9 option exercises. In 2026 alone, the filings show no purchases and 4 sales.
The newest entry dates from 26 August 2026: a transaction, in Ocular Therapeutix, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 34 declarations